CONMED Beats Q2 Views, Raises EPS Guidance on Strong Organic Growth
CNMD sits 37% above its 52-week low of $31.44.
Summary
CONMED delivered Q2 adjusted EPS of $1.38, beating expectations and up 20% year-over-year, driven by 6% organic constant currency sales growth excluding GI exits. The beat was aided by a $0.21 tariff refund benefit. Management raised full-year adjusted EPS guidance to $4.48-$4.60, up from $4.30-$4.45, while narrowing revenue guidance to $1.358B-$1.373B. This follows a period of strategic moves including debt refinancing, board and CFO appointments, and the AirSeal FDA clearance expansion. The results and raised outlook reinforce the turnaround narrative amid ongoing takeover speculation reported earlier this month.
At the time of this announcement, CNMD was trading at $43.21 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $31.44 to $56.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.